Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
229 hedge funds and large institutions have $1.09B invested in Catalyst Pharmaceutical in 2022 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 66 increasing their positions, 67 reducing their positions, and 24 closing their positions.
175% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 24
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
138% more capital invested
Capital invested by funds: $459M → $1.09B (+$634M)
25% more call options, than puts
Call options by funds: $2.9M | Put options by funds: $2.31M
21% more funds holding
Funds holding: 189 → 229 (+40)
9.36% more ownership
Funds ownership: 73.45% → 82.81% (+9.4%)
1% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 67
Top Buyers
| 1 |
BlackRock
New York
|
+$98.6M |
| 2 |
DM
Deerfield Management
New York
|
+$58M |
| 3 |
State Street
Boston,
Massachusetts
|
+$25.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.1M |
| 5 |
Two Sigma Investments
New York
|
+$15.1M |
Top Sellers
| 1 |
RA
Royce & Associates
New York
|
-$17.1M |
| 2 |
Millennium Management
New York
|
-$15.2M |
| 3 |
Goldman Sachs
New York
|
-$14.1M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$10.1M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$7.68M |
CPRX Hedge Fund Activity: Q3 2022 in Review
229 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2022, worth a combined $1.09B — up 138% from $459M a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new CPRX positions and 24 closed out — a net gain of 42 holders — while 66 added to existing stakes and 67 trimmed.
The largest buyer was BlackRock, adding an estimated $98.6M. The largest seller was Royce & Associates, cutting an estimated $17.1M.
- 229 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2022, up from 189 in Q2 2022.
- Funds reported $1.09B of Catalyst Pharmaceutical stock for Q3 2022, up 138% quarter-over-quarter.
- 66 funds opened new Catalyst Pharmaceutical positions in Q3 2022 and 24 closed out, a net change of +42 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2022 was BlackRock, an estimated $98.6M added.
- The largest Catalyst Pharmaceutical seller in Q3 2022 was Royce & Associates, an estimated $17.1M sold.
Based on aggregated 13F filings for Q3 2022.